Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01432015 · ClinicalTrials.gov registry record · Phase 4
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
A Phase 4 study, sponsored by Gynecologic Oncology Associates.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT01432015: Completed Phase 4 study, sponsored by Gynecologic Oncology Associates.
NCT01432015 is a Phase 4 study that has completed, run by Gynecologic Oncology Associates. The registered enrollment target is 20 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01432015, a Phase 4 study, has completed, sponsored by Gynecologic Oncology Associates.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
Nausea and vomiting are two of the more concerning adverse outcomes associated with chemotherapy in the treatment of gynecologic malignancies. In fact, nearly 90% of cancer patients develop chemotherapy induced nausea and vomiting (CINV) following treatment with carboplatin and paclitaxel. The successful control of chemotherapy induced nausea and vomiting (CINV) is thus, of paramount importance in ensuring optimal treatment and sustaining a cancer patient's quality of life.
Primary Outcome
no emetic episodes or rescue therapy following the initiation of chemotherapy
Interventions
- OTHER Oral Placebo
- DRUG aprepitant
- DRUG fosaprepitant
- OTHER IV placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-03 |
| Phase | Phase 4 |
What the finished NCT01432015 record still lists
NCT01432015 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 4 interventions - of which Oral Placebo is the first listed.
NCT01432015 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01432015 about?
NCT01432015 is a clinical study titled "Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting". Nausea and vomiting are two of the more concerning adverse outcomes associated with chemotherapy in the treatment of gynecologic malignancies. In fact, nearly 90% of cancer patients develop chemotherapy induced nausea and vomiting (CINV) following treatment with carboplatin and paclitaxel. The succe...
What is the current status of trial NCT01432015?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2011-09. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01432015?
The interventions under investigation include: Oral Placebo (OTHER), aprepitant (DRUG), fosaprepitant (DRUG), IV placebo (OTHER).
Who is sponsoring clinical trial NCT01432015?
This trial is sponsored by Gynecologic Oncology Associates, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01432015's enrollment target sits among peer trials
20 1753rd of 2000 higher than 167 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia